Financing will support SHINE's four-phased approach to fusion, and accelerate the domestic production of medical isotopes JANESVILLE, Wis., Oct. 11, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced it has raised $70 million in additional funding.

融资将支持SHINE的四阶段融合方法，并加速医疗同位素的国内生产JANESVILLE，Wis。，2023年10月11日/PRNewswire/-下一代融合技术公司SHINE Technologies，LLC今天宣布它已经筹集了7000万美元的额外资金。

The round was led by existing investors including Baillie Gifford and Fidelity Management & Research Company, and also includes participation from new institutional investors. This round will complete the commercialization and scale-up of the company's near-term applications of fusion technology, which are used in the industrial, defense, and healthcare markets..

该轮由现有投资者领导，包括Baillie Gifford和Fidelity Management＆Research Company，还包括新机构投资者的参与。这一轮将完成公司在工业，国防和医疗保健市场中使用的融合技术近期应用的商业化和规模化。。

Continue Reading

继续阅读

SHINE is deploying a four-phased approach that commercializes fusion today while scaling its technology into the future. This approach provides important near-term economic and social benefits, while building a profitable foundation for the company to sustainably grow toward its longer term objectives in energy..

SHINE正在部署一种四阶段方法，将融合商业化，同时将其技术扩展到未来。这种方法提供了重要的近期经济和社会效益，同时为公司在能源方面的长期目标可持续发展奠定了有利可图的基础。。

From the beginning our purpose has been to deliver cost-effective fusion technologies to help the world. Greg Piefer CEO

从一开始，我们的目标就是提供具有成本效益的融合技术来帮助世界。Greg Piefer首席执行官

Tweet this

推特这个

'From the beginning, our purpose has been to deliver cost-effective fusion technologies to help the world, with a long term goal of providing cost-effective fusion energy. Our approach is differentiated in that it's grounded in a pragmatic, market-driven path. This financing is expected to carry us through several major inflection points, including profitability as we continue to refine fusion technology to solve today's problems in medicine, manufacturing, energy and beyond,' said Greg Piefer, founder and CEO of SHINE.

“从一开始，我们的目标就是提供具有成本效益的融合技术来帮助世界，长期目标是提供具有成本效益的融合能源。我们的方法有所不同，因为它以务实的市场驱动路径为基础。SHINE的创始人兼首席执行官格雷格·皮弗（Greg Piefer）说，预计这项融资将为我们带来几个重大转折点，包括盈利能力，因为我们继续完善融合技术，以解决当今医药，制造，能源等问题。

'We're now ramping our production of Lu-177 to get life-saving medicine to  cancer patients more quickly. It's the latest use of our technology to improve the world, and adds to our neutron inspection and radiation effects testing businesses, which are helping ensure people are safe through applications in aerospace, space and defense.

“我们现在正在努力生产Lu-177，以便更快地为癌症患者提供救生药物。这是我们技术用于改善世界的最新用途，并增加了我们的中子检查和辐射效应测试业务，这些业务通过在航空航天，太空和国防领域的应用帮助确保人们的安全。

Ultimately, these success stories will build value, as well as the skills and credibility needed to achieve our ultimate goal of achieving affordable fusion energy.'.

最终，这些成功案例将建立价值，以及实现实现我们实现负担得起的融合能源最终目标所需的技能和信誉。

This summer, SHINE announced the opening of Cassiopeia, the largest lutetium-177 production facility in North America. The company is now finalizing the commissioning of the facility, which is expected to become operational at the end of this year. SHINE made its first commercial sales of Lu-177 in 2020.Lu-177 is a radioactive agent that, when paired with a cancer-seeking molecule, delivers highly targeted radiation to cancer metastases, killing cancer cells while minimizing damage to surrounding healthy cells.

今年夏天，SHINE宣布开设北美最大的l-177生产设施Cassiopeia。该公司目前正在完成该设施的调试，预计该设施将于今年年底投入运营。SHINE于2020年首次商业销售Lu-177.Lu-177是一种放射性药物，与寻求癌症的分子配对后，可为癌症转移提供高度靶向的辐射，杀死癌细胞，同时最大限度地减少对周围健康细胞的损害。

At full capacity, the facility is expected to be capable of producing up to 200,000 doses of life-saving treatment per year. At a time when vital pharmaceuticals and therapy treatments are in limited supply, this financing will accelerate U.S.-based production and commercialization of critical medical isotopes used in millions of procedures annually.  'The success of Lu-177-based cancer treatments in extending patients' lives around the world is exciting.

预计该设施将满负荷，每年可生产多达200000剂救生处理。在重要药物和治疗供应有限的时候，这项融资将加速美国每年数百万程序中使用的关键医疗同位素的生产和商业化。基于Lu-177的癌症治疗在延长全球患者生活方面的成功令人兴奋。

SHINE's unique approach is solving critical problems in the radioisotope supply chain and helping get these medicines to the people who need them,' said Luke Ward, Investment Manager at Baillie Gifford. 'We look forward to continuing our partnership as SHINE scales its fusion technology to tackle even bigger challenges and create a safer, healthier and cleaner world.' To learn more about SHINE and its four phased approach to fusion please visit https://www.shinefusion.comAbout SHINE TechnologiesSHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach.

SHINE独特的方法是解决放射性同位素供应链中的关键问题，并帮助将这些药物提供给需要它们的人，“Baillie Gifford投资经理卢克·沃德说。”我们期待继续我们的合作伙伴关系，因为SHINE扩展了其融合技术，以应对更大的挑战并创造更安全，更健康和更清洁的世界要了解更多关于SHINE及其四阶段融合方法的信息，请访问https://www.shinefusion.comAboutSHINE技术SHINE以逐步的方式部署其安全，经济和环保的融合技术。

Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE's proprietary medical isotope production processes currently create non-carrier-added lutetium-177 and a.

其系统用于检查航空航天，国防，能源等领域的工业部件。SHINE专有的医疗同位素生产工艺目前正在创建非载体添加的l-177和a。